Jefferies Group Reiterates “GBX 1,650” Price Target for GlaxoSmithKline (GSK)
Other research analysts have also issued reports about the company. Liberum Capital reaffirmed a buy rating and set a GBX 1,760 ($23.87) target price on shares of GlaxoSmithKline in a research report on Monday, January 15th. Beaufort Securities raised GlaxoSmithKline to a buy rating and raised their target price for the stock from GBX 1,450 ($19.67) to GBX 1,500 ($20.35) in a research report on Thursday, February 8th. Berenberg Bank lowered their target price on GlaxoSmithKline from GBX 1,760 ($23.87) to GBX 1,705 ($23.13) and set a buy rating for the company in a research report on Thursday, February 8th. UBS set a GBX 1,550 ($21.03) target price on GlaxoSmithKline and gave the stock a buy rating in a research report on Thursday, February 8th. Finally, Goldman Sachs set a GBX 1,775 ($24.08) target price on GlaxoSmithKline and gave the stock a buy rating in a research report on Thursday, February 8th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of GBX 1,556.14 ($21.11).
GlaxoSmithKline opened at GBX 1,488.60 ($20.19) on Monday, according to MarketBeat.com. GlaxoSmithKline has a twelve month low of GBX 1,235.20 ($16.76) and a twelve month high of GBX 1,724.50 ($23.39).
The firm also recently disclosed a dividend, which will be paid on Thursday, July 12th. Stockholders of record on Thursday, May 10th will be given a GBX 19 ($0.26) dividend. This represents a dividend yield of 1.35%. The ex-dividend date is Thursday, May 10th.
In other news, insider Philip R. Hampton bought 3,028 shares of the firm’s stock in a transaction that occurred on Wednesday, April 25th. The stock was acquired at an average cost of GBX 1,445 ($19.60) per share, with a total value of £43,754.60 ($59,352.41). Also, insider Patrick Vallance sold 14,022 shares of the business’s stock in a transaction dated Monday, February 19th. The shares were sold at an average price of GBX 1,318 ($17.88), for a total value of £184,809.96 ($250,691.75). Over the last three months, insiders bought 3,046 shares of company stock valued at $4,400,370.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.